title: Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
abstract: OBJECTIVE
  This study investigated the long-acting antidiabetic efficacy of PEGylated fibroblast growth factor (FGF)-21 in type 2 diabetic db/db mice.
  
  
  METHODS
  PEGylated FGF-21 was prepared by modifying the N-terminus of human FGF-21 (hFGF-21) using mPEG-ALD. To compare the long-lasting hypoglycaemic effects of PEGylated FGF-21 and insulin glargine in diabetic db/db mice, their pharmacological efficacy was evaluated by changes in blood glucose levels, body weight, insulin levels, glycosylated haemoglobin levels, lipid profile and liver function parameters, and by oral glucose tolerance tests (OGTTs).
  
  
  RESULTS
  Both PEGylated FGF-21 and insulin glargine decreased plasma glucose in db/db mice. However, compared with insulin glargine treatment, PEGylated FGF-21 therapy had more significant effects in lowering blood glucose and glycosylated haemoglobin levels, improving lipid profile and liver function parameters, alleviating insulin resistance and reducing the glucose area under the curve in OGTTs.
  
  
  CONCLUSIONS
  Our results suggest that PEGylated FGF-21 is an ideal candidate as a long-acting antidiabetes drug, and holds significant promise as an effective therapeutic agent in the treatment of type 2 diabetes patients.
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: X
authors.initials: X
authors.lastname: Ye
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: J
authors.initials: J
authors.lastname: Qi
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: D
authors.initials: D
authors.lastname: Yu
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: P
authors.initials: P
authors.lastname: Xu
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.affiliation: School of Food Science and Technology, Jiangnan University, State Key Laboratory of Food Science and Technology, Wuxi, China.
authors.forename: S
authors.initials: S
authors.lastname: Zhu
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.
authors.forename: G
authors.initials: G
authors.lastname: Ren
authors.affiliation: Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China; Key Laboratory of Agricultural Biological Functional Gene, Northeast Agricultural University, Harbin, China. Electronic address: deshanli@163.com.
authors.forename: D
authors.initials: D
authors.lastname: Li
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004435:Eating / Q000187:drug effects; D005346:Fibroblast Growth Factors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; C414620:fibroblast growth factor 21; D000069036:Insulin Glargine; D011092:Polyethylene Glycols; D005346:Fibroblast Growth Factors
keywords: Diabetes; FGF-21; Hypoglycaemic effect; Insulin glargine; PEGylation